Last reviewed 2026-04-23 · How we verify

MK0991, caspofungin acetate

Inhibits the synthesis of beta-1,3-D-glucan, a critical component of fungal cell walls.

Inhibits the synthesis of beta-1,3-D-glucan, a critical component of fungal cell walls. Used for Invasive aspergillosis, Candidemia, Esophageal candidiasis.

At a glance

Mechanism of action

Caspofungin acetate works by targeting the enzyme glucan synthase, which is essential for the production of beta-1,3-D-glucan in fungal cell walls.

Approved indications

• Invasive aspergillosis
• Candidemia
• Esophageal candidiasis

Common side effects

• Nausea
• Vomiting
• Diarrhea

Key clinical trials

• A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
• Pharmacokinetics of Caspofungin in Burn Patients (PHASE2, PHASE3)
• PK/PD of Caspofungin in Children Severe Infection
• Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
• A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (PHASE3)
• Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study) (PHASE4)
• Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems (PHASE2)
• A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.